These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Koch M; Dezi A; Ferrario F; Capurso I Arch Intern Med; 1996 Nov; 156(20):2321-32. PubMed ID: 8911239 [TBL] [Abstract][Full Text] [Related]
25. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Goldstein JL; Huang B; Amer F; Christopoulos NG Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480 [TBL] [Abstract][Full Text] [Related]
26. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors. Lazzaroni M; Bianchi Porro G Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473 [TBL] [Abstract][Full Text] [Related]
27. Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression. Lad R; Armstrong D Can J Gastroenterol; 1999 Mar; 13(2):135-42. PubMed ID: 10203432 [TBL] [Abstract][Full Text] [Related]
28. [Antisecretory drugs and prophylaxis of secondary gastrointestinal effects associated with the consumption of non steroid anti-inflammatory drugs]. Lanas A; Arroyo MT Med Clin (Barc); 2000; 114 Suppl 2():57-62. PubMed ID: 10916808 [TBL] [Abstract][Full Text] [Related]
32. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms. Laine L Rev Gastroenterol Disord; 2003; 3 Suppl 4():S30-9. PubMed ID: 14671512 [TBL] [Abstract][Full Text] [Related]
33. [Misoprostol in the prevention of gastric erosions caused by nonsteroidal anti-inflammatory agents]. Delmas PD; Lambert R; Capron MH Rev Rhum Ed Fr; 1994 Feb; 61(2):126-31. PubMed ID: 7920500 [TBL] [Abstract][Full Text] [Related]
36. The impact of nonsteroidal anti-inflammatory drug-induced gastropathy. Scheiman JM Am J Manag Care; 2001 Feb; 7(1 Suppl):S10-4. PubMed ID: 11225347 [TBL] [Abstract][Full Text] [Related]
37. Treatment of nonsteroidal anti-inflammatory drug-associated gastric and duodenal damage. Efficacy of antisecretory drugs and mucosal protective compounds. Pipkin G; Mills JG Dig Dis; 1995 Jan; 13 Suppl 1():75-88. PubMed ID: 7697904 [TBL] [Abstract][Full Text] [Related]
38. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Scarpignato C; Pelosini I Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472 [TBL] [Abstract][Full Text] [Related]
39. [Efficacy of prostaglandin derivatives and mucoprotective drugs in treatment and prevention for NSAIDs-induced ulcer]. Fujikawa Y; Watanabe T; Tominaga K; Fujiwara Y; Sato H; Arakawa T Nihon Rinsho; 2011 Jun; 69(6):1039-43. PubMed ID: 21688624 [TBL] [Abstract][Full Text] [Related]
40. Cytoprotection with misoprostol: use in the treatment and prevention of ulcers. Ballinger A Dig Dis; 1994; 12(1):37-45. PubMed ID: 8200123 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]